Bone from blood:​ characteristics and clinical implications of circulating osteogenic progenitor (COP) cells

Feehan, Jack<sup>1,2</sup>; Kassem, Moustapha<sup>3,4</sup>; Pignolo, Robert J.<sup>5</sup>; Duque, Gustavo<sup>1,2</sup>

Affiliations

¹Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, VIC, Australia

²Department of Medicine, University of Melbourne–Western Health, Melbourne, VIC, Australia

³Molecular Endocrinology Laboratory (KMEB), Department of Endocrinology, Odense University Hospital & University of Southern Denmark, Odense, Denmark

⁴Department of Cellular and Molecular Medicine, The Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark

⁵Department of Medicine, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract and keywords

Circulating osteogenic progenitor (COP) cells are a population of cells in the peripheral blood with the capacity for bone formation, as well as broader differentiation into mesoderm‐like cells in vitro. Although some of their biological characteristics are documented in vitro, their role in diseases of the musculoskeletal system remains yet to be fully evaluated. In this review, we provide an overview of the role of COP cells in a number of physiological and pathological conditions, as well as identify areas for future research. In addition, we suggest possible areas for clinical utilization in the management of musculoskeletal diseases.

Keywords: CIRCULATING OSTEOGENIC PRECURSOR CELLS; COP CELLS; FRACTURE; FRAILTY; HETEROTOPIC OSSIFICATION; OSTEOPOROSIS; VASCULAR CALCIFICATION

Links

DOI: 10.1002/jbmr.4204

PubMed: 33118647

WoS: 000588549600001

History

Received: 2020-08-27

Revised: 2020-10-22

Accepted: 2020-10-23

Online: 2020-11-12

Cited Works (3)

Year	Entry
2006	Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. August 2006;8(4):315-317.
2020	Lee K, Lee KJ, Kim T, Hutomo F, Sun HJ, Cheon GJ, Park SI, Cho SW, Im S. Circulating osteocalcin‐positive cells as a novel diagnostic biomarker for bone metastasis in breast cancer patients. J Bone Miner Res. October 2020;35(10):1838-1849.
2006	Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. May 2006;38(5):525-528.

Cited By (1)

Year	Entry
2023	Cao G, Zhang S, Wang Y, Quan S, Yue C, Yao J, Alexander PG, Tan H. Pathogenesis of acquired heterotopic ossification: risk factors, cellular mechanisms, and therapeutic implications. Bone. March 2023;168:116655.